Embecta Corp.
General ticker "EMBC" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $556.8M (TTM average)
Embecta Corp. does not follow the US Stock Market performance with the rate: -36.7%.
Estimated limits based on current volatility of 2.3%: low 6.19$, high 6.48$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-08-27, amount 0.01$ (Y0.64%)
- Total employees count: 1850 (-11.9%) as of 2025
- US accounted for 53.6% of revenue in the fiscal year ended 2025-09-30
- Top business risk factors: Market competition, Market concentration, Tech breakthroughs, Supply chain disruptions, Regulatory and compliance
- Current price 22.2% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [8.75$, 17.40$]
- 2026-09-30 to 2027-09-30 estimated range: [8.06$, 16.29$]
Financial Metrics affecting the EMBC estimates:
- Positive: with PPE of 4.8 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 22.41
- Negative: Shareholder equity ratio, % of -59.69 <= 7.04
- Positive: 15.29 < Operating cash flow per share per price, % of 23.11
- Positive: -51.61 < Industry operating profit margin (median), % of -19.48
- Negative: Investing cash flow per share per price, % of -1.12 <= -0.14
- Negative: Return on assets ratio (scaled to [-100,100]) of 8.04 <= 10.70
- Positive: -6.44 < Industry operating cash flow per share per price (median), % of -3.27
- Negative: 0.41 < Inventory ratio change, % of 0.94
Short-term EMBC quotes
Long-term EMBC plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $1,120.80MM | $1,123.10MM | $1,080.40MM |
| Operating Expenses | $899.30MM | $956.30MM | $838.30MM |
| Operating Income | $221.50MM | $166.80MM | $242.10MM |
| Non-Operating Income | $-115.80MM | $-122.60MM | $-105.80MM |
| Interest Expense | $107.00MM | $112.30MM | $107.30MM |
| R&D Expense | $85.20MM | $78.80MM | $37.30MM |
| Income(Loss) | $105.70MM | $44.20MM | $136.30MM |
| Taxes | $35.30MM | $-34.10MM | $40.90MM |
| Net Income(Loss)* | $70.40MM | $78.30MM | $95.40MM |
| Stockholders Equity | $-821.70MM | $-738.30MM | $-651.20MM |
| Inventory | $152.10MM | $171.50MM | $178.60MM |
| Assets | $1,214.40MM | $1,285.30MM | $1,090.90MM |
| Operating Cash Flow | $67.70MM | $35.70MM | $191.70MM |
| Capital expenditure | $26.50MM | $15.80MM | $9.30MM |
| Investing Cash Flow | $-26.50MM | $-15.80MM | $-9.30MM |
| Financing Cash Flow | $-48.70MM | $-73.40MM | $-226.70MM |
| Earnings Per Share** | $1.23 | $1.34 | $1.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.